BELITE BIO, INC
No SEC Form 4 filings for $BLTE in the last 30 days.
Belite Bio's stock experienced a significant rise after the company announced its first-quarter earnings, which surpassed market expectations. This positive financial performance indicates potential growth and investor confidence in the company's outlook.
Belite Bio has initiated a rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Tinlarebant. This drug is intended for the treatment of Stargardt Disease. The news, reported by Reuters and Refinitiv, indicates a significant step forward in the development of this potential treatment.
Belite Bio, Inc. (BLTE) reported that its non-GAAP net loss widened in the fourth quarter. The company posted an adjusted net loss of $0.38 per share for the quarter ending December 31, 2025. This news comes alongside other recent company updates, including the completion of enrollment for its Stargardt Disease treatment trial and several analyst initiations with "Buy" ratings and price targets above $190.
